Realta Life Sciences secured an additional $40 million in the final tranche of its Series A, bringing total funding to more than $150 million. The biotech is developing a treatment for hypoxic ischemic encephalopathy, a serious neonatal brain injury condition with limited time windows for intervention. The funding increase provides runway for advancing the candidate through later-stage development and commercial planning if clinical endpoints continue to support efficacy.